{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:27Z","timestamp":1785387567042,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Introduction: Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers, with a subset progressing to locally advanced (laSCC) or metastatic (mSCC) stages. The introduction of anti-PD1 immunotherapy has transformed treatment, but real-world data remain limited, particularly in immunosuppressed patients. Methods: This single-centre, retrospective study included 189 patients with advanced cSCC treated between 2012 and 2022. Demographic, clinical, and treatment data were analyzed to assess clinical management and outcomes before and after the introduction of anti-PD1. Results: Among the 189 patients, 72.5% were male, with a median age of 79 years. Overall, 86 patients presented with laSCC and 103 with mSCC. In 100 patients, a preceding primary cSCC was documented, and its complete resection (R0) was associated with significantly better overall survival (OS) after diagnosis of advanced disease (p &lt; 0.001). Immunosuppressed patients, including organ transplant recipients and those with chronic lymphocytic leukemia (CLL), had significantly reduced OS (p = 0.017 and p = 0.0059, respectively). First-line treatment prior to 2018 predominantly involved surgery and radiotherapy. Following the introduction of anti-PD1 therapy, its use increased rapidly in both first- and second-line settings. From 2018 onward, the number of advanced cSCC cases discussed at the multidisciplinary tumorboard increased approximately threefold. Median OS was significantly longer for mSCC patients treated in the post-2018 era (p = 0.025), while the survival disadvantage of CLL patients compared to non-CLL patients widened, suggesting limited benefit from advances in systemic therapy in this subgroup. Best overall response to first-line anti-PD1 correlated significantly with OS, with complete responders achieving a 1-year progression-free survival of 83.3%. Conclusions: The introduction of anti-PD1 has demonstrated improved survival outcomes in advanced cSCC, though significant challenges remain for immunosuppressed patients, particularly those with CLL and solid organ transplant recipients. Future research should focus on optimizing treatment for these high-risk groups, therapeutic sequencing, and the role of perioperative (neoadjuvant and adjuvant) immunotherapy strategies.<\/jats:p>","DOI":"10.3390\/curroncol33080449","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:11:56Z","timestamp":1785168716000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-9596","authenticated-orcid":false,"given":"Ramon","family":"Staeger","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra Gioia","family":"Ehrat","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kamber","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"},{"name":"Department of Dermatologie, Kantonsspital Aarau, 5000 Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam C.","family":"N\u00e4geli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Medical Faculty, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2023.01.017","article-title":"Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland","volume":"183","author":"Keim","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamadermatol.2013.2139","article-title":"Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell Carcinoma: A 10-Year, Single-Institution Cohort Study","volume":"149","author":"Schmults","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113251","DOI":"10.1016\/j.ejca.2023.113251","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113252","DOI":"10.1016\/j.ejca.2023.113252","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bjd.15931","article-title":"Epidemiology of keratinocyte carcinomas after organ transplantation","volume":"177","author":"Madeleine","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/ijd.15813","article-title":"Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: A systematic review of the literature","volume":"61","author":"Lai","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaoto.2019.3751","article-title":"Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"146","author":"Tam","year":"2020","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","article-title":"The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature","volume":"9","author":"Inman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","first-page":"12","article-title":"Swiss Recommendations for Systemic Therapies in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma","volume":"8","author":"Mangana","year":"2021","journal-title":"Heal. TIMES Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e002757","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"(2026, July 23). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2020.07.029","article-title":"Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: Real-world data of a retrospective, multicenter study","volume":"138","author":"Salzmann","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hober, C., Fredeau, L., Pham-Ledard, A., Boubaya, M., Herms, F., Celerier, P., Aubin, F., Beneton, N., Dinulescu, M., and Jannic, A. (2021). Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. Cancers, 13.","DOI":"10.1016\/j.annonc.2020.08.1210"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Strippoli, S., Fanizzi, A., Quaresmini, D., Nardone, A., Armenio, A., Figliuolo, F., Filotico, R., Fucci, L., Mele, F., and Traversa, M. (2021). Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.686308"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jid.2017.06.025","article-title":"Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study","volume":"137","author":"Eigentler","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: A prospective study","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/jdv.18101","article-title":"Risk factors for incomplete excision of cutaneous squamous cell carcinoma: A large cohort study","volume":"36","author":"Marsidi","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e14978","DOI":"10.1111\/exd.14978","article-title":"Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis","volume":"33","author":"Pham","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e35920","DOI":"10.1002\/cncr.35920","article-title":"Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023\u20132024","volume":"131","author":"Wallace","year":"2025","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5694\/mja2.52199","article-title":"Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: A retrospective real world cohort study","volume":"220","author":"McLean","year":"2024","journal-title":"Med. J. Aust."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ajd.13994","article-title":"Metastatic squamous cell carcinoma in chronic lymphocytic leukaemia in a haematology\u2013dermatology multidisciplinary clinic","volume":"64","author":"Lai","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Grywalska, E., Zaborek, M., \u0141yczba, J., Hrynkiewicz, R., B\u0119bnowska, D., Becht, R., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., and G\u00f3\u017ad\u017a, S. (2020). Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. Cells, 9.","DOI":"10.3390\/cells9112398"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100882","DOI":"10.1016\/j.trre.2024.100882","article-title":"Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies","volume":"38","author":"Struckmeier","year":"2024","journal-title":"Transplant. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jaad.2024.01.040","article-title":"Cumulative incidence and risk factors for cutaneous squamous cell carcinoma metastases in organ transplant recipients: The Skin Care in Organ Transplant Patients in Europe-International Transplant Skin Cancer Collaborative metastases study, a prospective multicenter study","volume":"90","author":"Genders","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1080\/09546634.2022.2118516","article-title":"Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients","volume":"33","author":"Hanania","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma","volume":"393","author":"Rischin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8937","DOI":"10.1245\/s10434-025-18035-9","article-title":"Response-Adapted Oncologic Surgery in Cutaneous Squamous Cell Carcinoma: A Paradigm Shift Following Neoadjuvant Immunotherapy","volume":"32","author":"Yaniv","year":"2025","journal-title":"Ann. Surg. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:37Z","timestamp":1785385297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080449"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080449","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}